GlassScriptPhysician profile
Silva Marinez Hamner
NPI 1043966211
$3,140.50
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,106 · 2023: $1,896 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $498.20 | 2022-2023 | Rexulti, Abilify Mycite, Nuedexta |
| Neurocrine Biosciences, INC. | $431.13 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $281.35 | 2022-2023 | |
| Abbvie INC. | $276.80 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $207.51 | 2022-2024 | Austedo Xr |
| Alkermes, INC. | $206.63 | 2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $184.86 | 2022-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $159.97 | 2022 | |
| Corium, LLC | $129.50 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $116.99 | 2022-2023 | Auvelity |
| Tris Pharma INC | $106.06 | 2022-2023 | Dyanavel Xr |
| Bausch Health US, LLC | $94.49 | 2022-2023 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $85.89 | 2022-2023 | Quviviq |
| Lundbeck LLC | $64.00 | 2022-2023 | Rexulti |
| Noven Therapeutics, LLC | $53.43 | 2023 | Xelstrym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $40.01 | 2022-2023 | Hetlioz, Fanapt |
| Merz Pharmaceuticals, LLC | $38.64 | 2023 | Xeomin |
| Supernus Pharmaceuticals, INC. | $33.47 | 2023 | Qelbree |
| Indivior INC. | $32.93 | 2022-2023 | Perseris |
| Neos Therapeutics, LP | $31.56 | 2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $27.76 | 2022-2023 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $13.95 | 2023 | Horizant |
| Avanir Pharmaceuticals, INC. | $13.54 | 2022 | |
| Brainsway USA INC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silva Hamner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.